Bilaver LA, et al. - Since peanut allergy (PA) affects 2.2% of children in the US, researchers analyzed the efficacy of a pediatrician-designed clinical decision support (CDS) tool and training on pediatrician adherence to the guidelines. Clinicians are advised to screen for PA risk for infants aged 4 to 6 months. High-risk infants (those with severe eczema and/or allergy to eggs) should receive a specific IgE (sIgE) or allergy referral for diagnosis prior to the introduction of peanut products, whereas low-risk or moderate-risk infants (with mild-moderate or no eczema) may have peanut products in their diet. Possible prevention of PA in infants is based on pediatricians adopting recommendations for infants aged 4 to 6 months in well-child visits. Findings suggested that CDS tools are an important way to enable doctors to adhere to clinical guidelines.